Adhera Therapeutics (ATRX) 10-Q 23 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 23, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-13789
Entity Registrant Name	ADHERA THERAPEUTICS, INC.
Entity Central Index Key	0000737207
Entity Tax Identification Number	11-2658569
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Innovation Parkway
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70820
City Area Code	(919)
Local Phone Number	518-3748
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,035,290

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash	$ 42	$ 1
Total current assets	42	1
Total assets	42	1
Current liabilities
Accounts payable	2,280	2,257
Due to related party	4	4
Accrued expenses	2,671	2,112
Accrued dividends	4,830	4,083
Term loan	5,677	5,677
Convertible notes payable, net	817	641
Derivative liability	103
Total current liabilities	16,382	14,774
Total liabilities	16,382	14,774
Commitments and contingencies (Note 7)
Stockholders’ deficit
Common stock, $0.006 par value; 180,000,000 shares authorized, 11,785,290 and 11,112,709 shares issued and outstanding as of June 30, 2021, and December 31, 2020, respectively	71	67
Additional paid-in capital	30,417	29,772
Accumulated deficit	(46,828)	(44,612)
Total stockholders’ deficit	(16,340)	(14,773)
Total liabilities and stockholders’ deficit	42	1
Series C Convertible Preferred Stock [Member]
Stockholders’ deficit
Series G convertible preferred stock, $0.01 par value, 6,000 shares designated; zero shares outstanding as of June 30, 2021, and December 31, 2020.
Series D Convertible Preferred Stock [Member]
Stockholders’ deficit
Series G convertible preferred stock, $0.01 par value, 6,000 shares designated; zero shares outstanding as of June 30, 2021, and December 31, 2020.
Series E Convertible Preferred Stock [Member]
Stockholders’ deficit
Series G convertible preferred stock, $0.01 par value, 6,000 shares designated; zero shares outstanding as of June 30, 2021, and December 31, 2020.
Series F Convertible Preferred Stock [Member]
Stockholders’ deficit
Series G convertible preferred stock, $0.01 par value, 6,000 shares designated; zero shares outstanding as of June 30, 2021, and December 31, 2020.
Series G Convertible Preferred Stock [Member]
Stockholders’ deficit
Series G convertible preferred stock, $0.01 par value, 6,000 shares designated; zero shares outstanding as of June 30, 2021, and December 31, 2020.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Common Stock, Par or Stated Value Per Share	$ 0.006
Common Stock, Shares Authorized	180,000,000
Common Stock, Shares, Outstanding	11,785,290	11,112,709
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,200	1,200
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference value	$ 510,000	$ 510,000
Series D Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.01
Preferred stock, shares authorized	220	220
Preferred stock, shares issued	40	40
Preferred stock, shares outstanding	40	40
Preferred stock, liquidation preference value	$ 12,000	$ 12,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.01
Preferred stock, shares authorized		3,500
Preferred stock, shares outstanding	3,450	3,458
Preferred stock, liquidation preference value	$ 17,250,000	$ 17,250,000
Series F Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,200	2,200
Preferred stock, shares issued	361	361
Preferred stock, shares outstanding	361	361
Preferred stock, liquidation preference value	$ 1,805,000	$ 1,805,000
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,000	6,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses
Sales and marketing	$ 8,000	$ 13,000	$ 17,000	$ 798,000
General and administrative	121,000	343,000	222,000	881,000
Total operating expenses	129,000	356,000	239,000	1,679,000
Loss from operations	(129,000)	(356,000)	(239,000)	(1,679,000)
Other income (expense)
Interest expense	(248,000)	(417,000)	(491,000)	(827,000)
Other income		40,000		40,000
Derivative expense	(87,000)		(87,000)
Amortization of debt discount	(50,000)	(173,000)	(125,000)	(278,000)
Total other income (expense)	(385,000)	(550,000)	(703,000)	(1,065,000)
Net loss	(514,000)	(906,000)	(942,000)	(2,744,000)
Dividends	(392,000)	(382,000)	(1,274,000)	(765,000)
Net Loss Applicable to Common Stockholders	$ (906,000)	$ (1,288,000)	$ (2,216,000)	$ (3,509,000)
Net loss per share –Common Stockholders - basic and diluted	$ (0.08)	$ (0.12)	$ (0.20)	$ (0.32)
Weighted average shares outstanding - basic and diluted	11,669,779	10,869,530	11,270,044	10,869,530

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock Series C [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series F [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019					$ 65,000	$ 29,375,000	$ (39,327,000)	$ (9,887,000)
Balance, shares at Dec. 31, 2019	100	40	3,478	361	10,869,530
Accrued and deemed dividend							(383,000)	(383,000)
Issuance of warrants with notes payable						239,000		239,000
Share based compensation						36,000		36,000
Net loss							(1,838,000)	(1,838,000)
Ending balance, value at Mar. 31, 2020					$ 65,000	29,650,000	(41,548,000)	(11,833,000)
Balance, shares at Mar. 31, 2020	100	40	3,478	361	10,869,530
Beginning balance, value at Dec. 31, 2019					$ 65,000	29,375,000	(39,327,000)	(9,887,000)
Balance, shares at Dec. 31, 2019	100	40	3,478	361	10,869,530
Net loss								(2,744,000)
Ending balance, value at Jun. 30, 2020					$ 65,000	29,674,000	(42,836,000)	(13,097,000)
Balance, shares at Jun. 30, 2020	100	40	3,478	361	10,869,530
Beginning balance, value at Mar. 31, 2020					$ 65,000	29,650,000	(41,548,000)	(11,833,000)
Balance, shares at Mar. 31, 2020	100	40	3,478	361	10,869,530
Accrued and deemed dividend							(382,000)	(382,000)
Share based compensation						(26,000)		(26,000)
Net loss							(906,000)	(906,000)
Benefical conversion feature - convertible notes						50,000		50,000
Ending balance, value at Jun. 30, 2020					$ 65,000	29,674,000	(42,836,000)	(13,097,000)
Balance, shares at Jun. 30, 2020	100	40	3,478	361	10,869,530
Beginning balance, value at Dec. 31, 2020					$ 67,000	29,772,000	(44,612,000)	(14,773,000)
Balance, shares at Dec. 31, 2020	100	40	3,458	361	11,112,709
Accrued and deemed dividend						505,000	(882,000)	(377,000)
Issuance of common stock for term loan conversion					$ 3,000	23,000		26,000
Issuance of common stock for term loan conversion, shares					518,000
Issuance of warrants with convertible notes						28,000		28,000
Net loss							(428,000)	(428,000)
Ending balance, value at Mar. 31, 2021					$ 70,000	30,328,000	(45,922,000)	(15,524,000)
Balance, shares at Mar. 31, 2021	100	40	3,458	361	11,630,709
Beginning balance, value at Dec. 31, 2020					$ 67,000	29,772,000	(44,612,000)	(14,773,000)
Balance, shares at Dec. 31, 2020	100	40	3,458	361	11,112,709
Net loss								(942,000)
Ending balance, value at Jun. 30, 2021					$ 71,000	30,417,000	(46,828,000)	(16,340,000)
Balance, shares at Jun. 30, 2021	100	40	3,450	361	11,785,290
Beginning balance, value at Mar. 31, 2021					$ 70,000	30,328,000	(45,922,000)	(15,524,000)
Balance, shares at Mar. 31, 2021	100	40	3,458	361	11,630,709
Accrued and deemed dividend						11,000	(392,000)	(381,000)
Issuance of warrants with convertible notes						69,000		69,000
Issuance of common stock for cashless exercise of warrants
Issuance of common stock for cashless exercise of warrants, shares					53,571
Issuance of common stock for Series E conversion					$ 1,000	9,000		10,000
Issuance of common stock for Series E conversion, shares			(8)		101,010,000
Net loss							(514,000)	(514,000)
Ending balance, value at Jun. 30, 2021					$ 71,000	$ 30,417,000	$ (46,828,000)	$ (16,340,000)
Balance, shares at Jun. 30, 2021	100	40	3,450	361	11,785,290

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows Used in Operating Activities:
Net loss	$ (942,000)	$ (2,744,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation		10,000
Derivative expense	87,000
Debt issuance expense	4,000	380,000
Amortization of debt discount	125,000	275,000
Accrued interest and dividends	487,000	449,000
Changes in operating assets and liabilities:
Prepaid expenses and other assets		226,000
Accounts payable	23,000	797,000
Accrued expenses	98,000	117,000
Net Cash Used in Operating Activities	(118,000)	(490,000)
Cash Flows Provided By Financing Activities:
Proceeds from loans	171,000	553,000
Notes payable issuance costs	(12,000)	(105,000)
Net Cash Provided by Financing Activities	159,000	448,000
Net increase (decrease) in cash	41,000	(42,000)
Cash – Beginning of Period	1,000	50,000
Cash - End of Period	42,000	8,000
Non-cash Investing and Financing Activities:
Issuance of warrants with notes payable	97,000	239,000
Issuance of common stock for conversion of debt	26,000
Conversion of Series E to common stock	1,000
Beneficial conversion feature on notes payable		50,000
Cashless exercise of warrants	4,000
Accrued and deemed dividends	$ 1,274,000	$ 765,000

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Nature of Operations, Basis of Presentation and Significant Accounting Policies	Note 1 – Nature of Operations, Basis of Presentation and Significant Accounting Policies Business Overview Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company. Previously, the Company was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. On January 4, 2021, the licensor terminated the licensing agreement for the product candidate. As of the date of this report, the Company is not engaged in any research, development, or commercialization activities, and is not generating any revenues from operations. On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. To the extent that resources have been available, the Company has continued to work with its advisors to restructure our company and to identify potential strategic transactions, including the Melior transaction described above. There can be no assurance that the Company will be successful in raising sufficient capital to meet its obligations under the Melior license agreement. If the Company does not raise substantial additional capital to develop and commercialize repay its indebtedness which is in default or restructure the indebtedness, it is likely that the Company will discontinue all operations and seek bankruptcy protection. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or for any future period. Principles of Consolidation The condensed consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2021, the Company had cash and cash equivalents of $ 42,000 and has negative working capital of approximately $ 16.3 million. The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $ 942,000 for the six months ended June 30, 2021. The Company had an accumulated deficit of approximately $ 46.8 million as of June 30, 2021. In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to us or at all. General market conditions, as well as market conditions for companies in our financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies Reclassification Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit. Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2021, the Company measured a conversion feature on an outstanding convertible note loan as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 103,000 . There were no liabilities or assets measured at fair value on a non-recurring basis as of June 30, 2021 and there were no Schedule of Fair Value Measurements Fair Value Measurements at June 30, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 103 $ 103 Total $ - $ - $ 103 $ 103 Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2021 2020 2021 2020 Three Months Ended Six Months Ended 2021 2020 2021 2020 Numerator Net loss $ (514 ) $ (906 ) $ (942 ) $ (2,744 ) Dividends (392 ) (382 ) (1,274 ) (765 ) Net Loss allocable to common stockholders $ (906 ) $ (1,288 ) $ (2,216 ) $ (3,509 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 11,669,779 10,869,530 11,270,044 10,869,530 Net loss per share of common stock, basic and diluted Net loss per share $ (0.08 ) $ (0.12 ) $ (0.20 ) $ (0.32 ) Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share For the Six Months ended June 30, 2021 2020 Convertible notes 20,952,683 14,411,530 Stock options outstanding 387,550 1,891,350 Warrants 59,836,767 53,770,750 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,325,770 40,895,882 Series F Preferred Stock 4,446,980 4,158,180 Total 129,066,417 115,244,359

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 2 – Notes Payable 2019 Term Loan During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes (the “Notes”) in the aggregate principal amount of approximately $ 5.7 million. The Company paid $ 707,000 in debt issuance costs which was recorded as a debt discount to be amortized as interest expense over the term of the loan using the straight-line method. The Notes accrue interest at a rate of 12 The unpaid principal balance of the Notes, plus accrued and unpaid interest thereon, will mature on the earliest to occur of: (i) June 28, 2020 (subject to extension for up to ( 60 On December 28, 2019, the Company defaulted on the initial interest payment on the loan and the interest rate per annum increased to the default rate of 15 %.On June 28, 2020, the Company defaulted on the maturity date principal payment. The Company recognized approximately $ 382,000 771,000 171,000 347,000 212,000 422,000 As of June 30, 2021, the Company had approximately $ 1.6 million of accrued interest on the notes included in accrued expenses and remains in default on the repayment of approximately $ 5.7 CONVERTIBLE PROMISSORY NOTES The following table summarizes the Company’s outstanding convertible notes as of June 30, 2021 and December 31, 2020: Schedule of Convertible Promissory Notes (in thousands) June 30, 2021 December 31, 2020 Convertible Notes $ 906 $ 720 Unamortized discounts (89 ) (79 ) $ 817 $ 641 Four convertible notes with outstanding principal of approximately $ 772,000 Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors pursuant to purchase: (i) original issue discount unsecured Convertible Promissory Notes (the “Notes”), with a principal of $ 550,500 10 % original issue discount, for a total purchase price of $ 499,950 , and (ii) warrants to purchase up to such number of shares of the common stock of the Company as is equal to the product obtained by multiplying 1.75 by the quotient obtained by dividing (A) the principal amount of the Notes by (B) the then applicable conversion price of the Notes. The maturity date is the six (6) month anniversary of the original issue date, or August 5, 2020, or such earlier date as the Note is required or permitted to be repaid as provided thereunder, and to pay interest to the Holder on the aggregate unconverted and then outstanding principal amount of the Note. Interest shall accrue to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of 10 On or after May 5, 2020, until the Notes are no longer outstanding, the Notes shall be convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price shall be the lower of: (i) $ 0.50 70 60 0.05 The exercise price of the Warrants shall be equal to the conversion price of the Notes, provided, that on the date that the Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of 18 The Company recognized $ 35,000 55,000 18,000 30,000 171,000 276,000 25,000 50,000 On March 19, 2021, the holder of the note converted $ 25,900 518,000 As of June 30, 2021, the Company had accrued interest on the note of approximately $ 99,000 As of June 30, 2021, the Company remains in default on the repayment of principal of $ 550,500 and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 140 Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10 58,055 52,500 10 14,000 The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.02 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 65 % of the lowest closing bid price of the Company’s common stock as reported on its principal trading market for the twenty consecutive trading day period ending on (and including) the trading day immediately preceding the date on which the conversion notice was delivered. The conversion price shall also be adjusted for subsequent equity sales by the Company. Because the share price on the commitment date was in excess of the conversion price, the Company recorded a beneficial conversion feature of $ 50,000 related to this note that was credited to additional paid in capital and reduced the carrying amount. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $ 203,000 . The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 For the three and six-month periods ended June 30, 2020, the Company recognized approximately $ 850 750 2,000 On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of 18 For the three months ended June 30, 2021, the Company recognized approximately $ 2,600 5,200 As of June 30, 2021, the Company remains in default on the repayment of principal of $ 58,055 10,000 140 As of June 30, 2021, the Company remains in default on the repayment of principal and interest on the notes. Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10 111,111 100,000 0.07 70 0.05 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. Additionally, the Company issued the noteholder 1,587,301 0.08 five The Company recorded approximately $ 9,000 The note matured on April 30, 2021. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10 % per annum, calculated on the basis of a 360-day year. The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 On March 19, 2021, the exercise price of the warrants was adjusted to $ 0.05 634,919 57,000 0.16 262.27 0.92 On April 30, 2021, the Company defaulted on the October 2020 term loan and the interest rate on the loan reset to 18 For the three and six-month periods ended June 30, 2021, the Company recognized approximately $ 5,000 9,700 1,000 2,600 20,000 79,000 As of June 30, 2021, the Company has outstanding principal of $ 111,111 8,000 . As of June 30, 2021, the Company remains in default on the repayment of principal and interest on the notes. Secured Convertible Promissory Note – January 2021 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10 52,778 47,500 0.07 70 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 753,968 0.08 The Company recorded approximately $ 2,000 The note matured on July 31, 2021. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on the basis of a 360-day year. The Company recorded a discount related to the warrants of approximately $ 32,000 3,000 1,000 0.45 240.83 one year The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 and debt issuance cost of $ 1,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. On March 19, 2021, the exercise price of the warrants was adjusted to $ 0.05 301,592 27,000 0.16 262.27 0.97 For the three and six-month periods ended June 30, 2021, the Company recognized approximately $ 1,700 2,900 400 700 11,000 29,000 No As of June 30, 2021, the Company has outstanding principal of $ 52,778 on the note, has recorded approximately $ 2,000 and approximately $ 5,700 and $ 100 in unamortized discount and issuance costs, respectively on the accompanying balance sheets. The Company defaulted on the principal and interest payment on the note on July 31, 2021. Upon demand for repayment at the election of the holder, the holder of the note is due 125 Secured Convertible Promissory Note – April 2021 On April 12 th, 10 % original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $ 66,667 , for a purchase price of $ 60,000 net of an original discount of $6,667 . Additionally, the Company issued to the investor 800,000 five -year warrants to purchase the Company’s common stock at an exercise price of $ 0.095 per share. The warrants have full ratchet protection. The note matures on October 12, 2021, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10 % per annum, calculated on-the-basis of a 360-day year. The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 70 The Company recorded a discount related to the warrants of approximately $ 34,000 and a discount related to the convertible debt original issue discount of $ 3,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of 0.89 %, volatility of 240.64 %, and an expected term of one year On June 25, 2021, the exercise price of the warrants was adjusted to $ 0.075 88,893 11,000 0.92 247.52 0.96 For the three and six-month period ended June 30, 2021, the Company recognized $ 16,000 1,500 No As of June 30, 2021, the Company has recorded $ 66,667 of principal and approximately $ 1,500 in interest and approximately $ 21,000 in unamortized discount and approximately $ 1,500 125 Secured Convertible Promissory Note – June 2021 On June 25, , 5 % original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $ 66,500 , for a purchase price of $ 63,000 . Additionally, the Company issued to the investor 800,000 three -year warrants to purchase the Company’s common stock at an exercise price of $ 0.095 per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain $ 76,000 which is a full ratchet price protection provision The note matures on June 25, 2022, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10 The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 0.08 65 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. The Company recorded approximately $ 9,000 The Company recorded a discount related to the warrants of approximately $ 61,000 and a discount related to the convertible debt of $ 5,000 based on the relative fair value of the instruments as determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.48 %, volatility of 302.11 %, and an expected term of 0.60 years in calculating the fair value of the warrants. In addition, the Company recorded approximately $ 90,000 for the conversion feature on the note as a derivative liability using the binomial valuation model. An additional $ 13,000 of expense was recognized as of June 30, 2021, for the change in the fair value of the derivative liability. Values were determined for the change in the fair value of the warrants based on assumptions for a risk-free rate of 0.09 %, volatility of 405 %, and an expected term of 0.20 year in calculating the fair value of the conversion features. At June 30, 2021 the Company has recorded $ 66,500 100 62,000

Licensing Agreements

Licensing Agreements	6 Months Ended
	Jun. 30, 2021
Licensing Agreements
Licensing Agreements	Note 3 - Licensing Agreements Les Laboratories Servier As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions). On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®. No Novosom Agreements In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom 51,988 75,000 45,000 20,000 25,000 The Company recognized $ 25,000 License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. An unpaid balance for previous years services performed under the agreement of approximately $ 4,000 is included in due to related party in the accompanying consolidated balance sheets for both periods ending June 30, 2021, and December 31, 2020.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders’ Equity	Note 5 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series B Preferred or Series A Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated 6,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”).The Company plans to file a certificate of elimination with respect to the Series B stock and a certificate of decrease with respect to each of its Series C, D and F Preferred stock. Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 666.67 votes per share 7.50 As of June 30, 2021, and December 31, 2020, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 1,250 votes per share 4.00 5 As of June 30, 2021, and December 31, 2020, 40 Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 8% 0.50 February 10, 2020 On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 0.50 0.05 25,900 518,000 390,000 0.16% 262.27% .41 .43 On May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. On June 8, 2021, an investor converted 8 10,000 101,010 53,571 75,000 As of June 30, 2021, the Company had a total of 30,405,600 warrants issued with Series E Preferred stock outstanding. The warrants expire in 2023. The Company had accrued dividends on the Series E Preferred stock of approximately $ 4.4 3.7 At June 30, 2021 and December 31, 2020, there were 3,450 3,458 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 8% 0.50 February 10, 2020 five years On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 0.50 0.05 25,900 518,000 31,000 0.16% 262.27% .46 .53 As of June 30, 2021, the Company had a total of 3,088,500 The Company had accrued dividends on the Series F Preferred stock of approximately $ 418,000 347,000 At June 30, 2021 and December 31, 2020, there were 361 Series F Preferred shares outstanding. Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 0.50 As of June 30, 2021, no Common Stock On March 19, 2021, the Company issued 518,000 25,900 On June 8, 2021, an investor converted 8 shares of Series E Preferred and accrued dividends of approximately $ 10,000 101,010 shares of common stock.. In addition, the Company issued 53,571 shares of common stock to the investor for a cashless exercise of 75,000 warrants. Warrants As of June 30, 2021, there were 59,836,767 0.09 Schedule of Stockholders' Equity Note, Warrants or Rights Warrant Summary: Expiry Shares 2021 2023 2024 2025 2026 Series D Preferred Stock 343,750 343,750 Series E Preferred Stock 30,405,600 30,405,600 Series F Preferred Stock 3,088,500 3,088,500 Convertible Notes 25,650,184 800,000 22,905,731 1,944,453 Other 348,733 10,080 335,452 3,201 Total Warrants 59,836,767 343,750 33,504,180 1,135,452 22,908,932 1,944,453 The above includes 58,344,284 price adjustable warrants. No warrants expired during the period. There were 75,000

Stock Incentive Plans

Stock Incentive Plans	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock Incentive Plans	Note 6 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the six months ended June 30, 2021. Share-based Payment Arrangement, Option, Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2020 391,350 $ 0.58 Options granted — — Options expired / forfeited (3,800 ) 2.60 Outstanding, June 30, 2021 387,550 0.99 Exercisable, June 30, 2021 387,550 $ 0.99 The following table summarizes additional information on stock options outstanding as of June 30, 2021. Share-based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.98 1.00 383,500 1.83 $ 0.98 383,500 $ 0.98 $ 1.70 4,050 .52 $ 1.70 4,050 $ 1.70 Totals 387,550 1.81 $ 0.99 387,550 $ 0.99 During the six months ended June 30, 2021, the Company granted no stock options. Total expense related to stock options was approximately $ 10,000 No As of June 30, 2021, the Company had no unrecognized compensation expense related to unvested stock options. As of June 30, 2021, the intrinsic value of stock options outstanding was zero.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Share Repurchase Agreement On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Except for the events discussed below, there were no subsequent events that required recognition or disclosure. Licensing Agreement On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5 Issuance of Common Stock On July 29, 2021, the Company issued 550,000 shares of common stock for the conversion of $ 27,500 of interest on the January 2020 convertible note. Secured Note Default On July 30, 2021, the Company defaulted under the Secured Convertible Promissory Note from January 2021 and the interest rate on the note reset to 18% Issuance of Common Stock On July 31, 2021, the Company issued 500,000 250,000 Warrant Expiration On August 7, 2021, 343,750 Issuance of Convertible Note On August 12, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the Buyer its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 10,500 100,000 The note matures one year from issuance and provides for an interest rate of 10% 0.075 0.08 20 In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of three years 0.095 Issuance of Convertible Note On August 18, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the Buyer its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 100,000 The note matures one year from issuance and provides for an interest rate of 10% per annum, payable at maturity, and is convertible into common stock of the Company at a price of $ 0.075 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $ 0.08 , the conversion price shall be reduced to 65% of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of three years 0.095

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Reclassification	Reclassification Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit.
Use of Estimates	Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2021, the Company measured a conversion feature on an outstanding convertible note loan as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 103,000 . There were no liabilities or assets measured at fair value on a non-recurring basis as of June 30, 2021 and there were no Schedule of Fair Value Measurements Fair Value Measurements at June 30, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 103 $ 103 Total $ - $ - $ 103 $ 103
Convertible Debt and Warrant Accounting	Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2021 2020 2021 2020 Three Months Ended Six Months Ended 2021 2020 2021 2020 Numerator Net loss $ (514 ) $ (906 ) $ (942 ) $ (2,744 ) Dividends (392 ) (382 ) (1,274 ) (765 ) Net Loss allocable to common stockholders $ (906 ) $ (1,288 ) $ (2,216 ) $ (3,509 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 11,669,779 10,869,530 11,270,044 10,869,530 Net loss per share of common stock, basic and diluted Net loss per share $ (0.08 ) $ (0.12 ) $ (0.20 ) $ (0.32 ) Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share For the Six Months ended June 30, 2021 2020 Convertible notes 20,952,683 14,411,530 Stock options outstanding 387,550 1,891,350 Warrants 59,836,767 53,770,750 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,325,770 40,895,882 Series F Preferred Stock 4,446,980 4,158,180 Total 129,066,417 115,244,359

Nature of Operations, Basis o_3

Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Schedule of Fair Value Measurements	Schedule of Fair Value Measurements Fair Value Measurements at June 30, 2021 Quoted Prices in Active Markets for Identical Assets Other Observable Inputs Significant Unobservable Inputs (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 103 $ 103 Total $ - $ - $ 103 $ 103
Schedule of Earnings Per Share, Basic and Diluted	The following table presents the computation of net loss per share (in thousands, except share and per share data): Schedule of Earnings Per Share, Basic and Diluted 2021 2020 2021 2020 Three Months Ended Six Months Ended 2021 2020 2021 2020 Numerator Net loss $ (514 ) $ (906 ) $ (942 ) $ (2,744 ) Dividends (392 ) (382 ) (1,274 ) (765 ) Net Loss allocable to common stockholders $ (906 ) $ (1,288 ) $ (2,216 ) $ (3,509 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 11,669,779 10,869,530 11,270,044 10,869,530 Net loss per share of common stock, basic and diluted Net loss per share $ (0.08 ) $ (0.12 ) $ (0.20 ) $ (0.32 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share For the Six Months ended June 30, 2021 2020 Convertible notes 20,952,683 14,411,530 Stock options outstanding 387,550 1,891,350 Warrants 59,836,767 53,770,750 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 43,325,770 40,895,882 Series F Preferred Stock 4,446,980 4,158,180 Total 129,066,417 115,244,359

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Convertible Promissory Notes	The following table summarizes the Company’s outstanding convertible notes as of June 30, 2021 and December 31, 2020: Schedule of Convertible Promissory Notes (in thousands) June 30, 2021 December 31, 2020 Convertible Notes $ 906 $ 720 Unamortized discounts (89 ) (79 ) $ 817 $ 641

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	As of June 30, 2021, there were 59,836,767 0.09 Schedule of Stockholders' Equity Note, Warrants or Rights Warrant Summary: Expiry Shares 2021 2023 2024 2025 2026 Series D Preferred Stock 343,750 343,750 Series E Preferred Stock 30,405,600 30,405,600 Series F Preferred Stock 3,088,500 3,088,500 Convertible Notes 25,650,184 800,000 22,905,731 1,944,453 Other 348,733 10,080 335,452 3,201 Total Warrants 59,836,767 343,750 33,504,180 1,135,452 22,908,932 1,944,453

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Option, Activity	The following table summarizes stock option activity for the six months ended June 30, 2021. Share-based Payment Arrangement, Option, Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2020 391,350 $ 0.58 Options granted — — Options expired / forfeited (3,800 ) 2.60 Outstanding, June 30, 2021 387,550 0.99 Exercisable, June 30, 2021 387,550 $ 0.99
Share-based Payment Arrangement, Option, Exercise Price Range	The following table summarizes additional information on stock options outstanding as of June 30, 2021. Share-based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.98 1.00 383,500 1.83 $ 0.98 383,500 $ 0.98 $ 1.70 4,050 .52 $ 1.70 4,050 $ 1.70 Totals 387,550 1.81 $ 0.99 387,550 $ 0.99

Schedule of Fair Value Measurem

Schedule of Fair Value Measurements (Details) $ in Thousands	Jun. 30, 2021USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, fair value	$ 103
Fair value of derivative liability	103
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, fair value
Fair value of derivative liability
Fair Value, Inputs, Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, fair value
Fair value of derivative liability
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, fair value	103
Fair value of derivative liability	$ 103

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Net loss	$ (514,000)	$ (428,000)	$ (906,000)	$ (1,838,000)	$ (942,000)	$ (2,744,000)
Dividends	(392,000)		(382,000)		(1,274,000)	(765,000)
Net Loss allocable to common stockholders	$ (906,000)		$ (1,288,000)		$ (2,216,000)	$ (3,509,000)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	11,669,779		10,869,530		11,270,044	10,869,530
Net loss per share	$ (0.08)		$ (0.12)		$ (0.20)	$ (0.32)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	129,066,417	115,244,359
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	66,667	66,667
Series D Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	50,000	50,000
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	43,325,770	40,895,882
Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	4,446,980	4,158,180
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	20,952,683	14,411,530
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	387,550	1,891,350
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	59,836,767	53,770,750

Nature of Operations, Basis o_4

Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 42,000				$ 42,000
Working captial	16,300,000				16,300,000
Net loss	514,000	$ 428,000	$ 906,000	$ 1,838,000	942,000	$ 2,744,000
Accumulated deficit	46,800,000				46,800,000
Fair Value, Net Asset (Liability)	0				0		$ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term Debt, Fair Value	$ 103,000				$ 103,000

Schedule of Convertible Promiss

Schedule of Convertible Promissory Notes (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes	$ 906	$ 720
Unamortized discounts	(89)	(79)
Convertible Notes Payable	$ 817	$ 641

Notes Payable (Details Narrativ

Notes Payable (Details Narrative)	Jun. 25, 2021USD ($)$ / shares	Apr. 16, 2021	Apr. 12, 2021USD ($)$ / sharesshares	Mar. 19, 2021USD ($)$ / sharesshares	Jan. 31, 2021USD ($)$ / sharesshares	Oct. 30, 2020USD ($)$ / sharesshares	Oct. 30, 2020USD ($)$ / sharesshares	Sep. 24, 2020$ / shares	Aug. 05, 2020	Jun. 26, 2020USD ($)	Jun. 15, 2020	May 05, 2020$ / shares	Feb. 05, 2020USD ($)	Aug. 05, 2019USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2021USD ($)	Jul. 31, 2021	Jul. 30, 2021	Apr. 30, 2021	Dec. 31, 2020USD ($)	Dec. 28, 2019
Short-term Debt [Line Items]
Amortization of debt issuance costs																	$ 4,000	$ 380,000
Accured interest															$ 100		100
Convertible Notes Payable, Current															817,000		817,000						$ 641,000
Debt discount to be amortized															89,000		89,000						$ 79,000
Amortization of debt discount																	125,000	275,000
Common stock conversion percentage						70.00%
Warrants term	three		five
Notes Payable															66,500		66,500
Debt Instrument, Unamortized Discount, Current															62,000		62,000
Derivative Liability, Fair Value, Gross Liability															103,000		103,000
Senior Secured Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Principal amount						$ 111,111	$ 111,111
Debt instrument, effective percentage						10.00%	10.00%															10.00%
Interest expense															5,000		9,700
Amortization of debt issuance costs															1,000		2,600
Convertible Notes Payable, Current						$ 100,000	$ 100,000
Debt Instrument, Convertible, Conversion Price | $ / shares				$ 0.05		$ 0.07	$ 0.07
Warrant term				11 months 1 day
Debt Instrument, Convertible, Beneficial Conversion Feature																	45,000
Intrinsic value of the beneficial conversion feature																	69,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				634,919		1,587,301	1,587,301
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 0.08	$ 0.08
Warrants term						five
Unamortized Debt Issuance Expense						$ 9,000	$ 9,000
Deemed dividend				$ 57,000
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs				0.16
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs				262.27
Senior Secured Convertible Promissory Note One [Member] | Valuation Technique, Option Pricing Model [Member]
Short-term Debt [Line Items]
Debt discount to be amortized															6,000		6,000
Unamortized Debt Issuance Expense															5,000		5,000
Senior Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Warrant term				11 months 19 days
Unamortized Debt Issuance Expense	$ 9,000
Deemed dividend					$ 27,000
Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs				0.16	0.45
Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs				262.27	240.83
Secured Promissory Note [Member]
Short-term Debt [Line Items]
Interest expense															1,500		1,500	0
Amortization of debt discount	$ 11,000														16,000		16,000
Secured Promissory Note [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument, effective percentage																					18.00%
Secured Promissory Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs	0.92
Secured Promissory Note [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs	247.52
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Debt discount to be amortized															66,000		66,000
Four Convertible Notes [Member]
Short-term Debt [Line Items]
Principal amount															772,000		772,000
Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Principal amount										$ 58,055
Debt Issuance Costs, Net										$ 14,000
Debt instrument, interest rate										10.00%
Debt instrument, effective percentage										10.00%
Interest expense															2,600	$ 850	5,200	850
Amortization of debt issuance costs																750		750
Convertible Notes Payable, Current										$ 52,500
Debt Instrument, Convertible, Conversion Price | $ / shares								$ 0.02
Debt conversion rate								65.00%
Amortization of debt discount																2,000		2,000
Debt default interest rate							1800.00%		18.00%
Debt Instrument, Convertible, Beneficial Conversion Feature										50,000
Intrinsic value of the beneficial conversion feature										203,000
Convertible Debt [Member] | Secured Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Principal amount															$ 58,055		$ 58,055
Debt instrument, interest rate															140.00%		140.00%
Accured interest															$ 10,000		$ 10,000
Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member]
Short-term Debt [Line Items]
Principal amount															111,111		111,111
Debt Issuance Costs, Net															4,000		4,000
Amortization of debt issuance costs															20,000		79,000
Accured interest															8,000		8,000
Amortization of debt discount																	5,000
Convertible Debt [Member] | Senior Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Amortization of debt issuance costs																	1,000
Debt conversion rate	65.00%
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,000
Derivative Liability, Fair Value, Gross Liability															13,000		13,000
Convertible Debt [Member] | Warrant [Member] | Senior Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Amortization of debt discount	5,000
Convertible Debt [Member] | Warrant [Member] | Secured Promissory Note [Member]
Short-term Debt [Line Items]
Amortization of debt discount			$ 3,000
Accredited Investors [Member] | Term Loan Subscription Agreements [Member]
Short-term Debt [Line Items]
Principal amount										$ 5,700,000				$ 5,700,000
Debt Issuance Costs, Net														$ 707,000,000,000
Debt instrument, interest rate														12.00%
Extension period for term of loan														60 days
Debt instrument, effective percentage																								15.00%
Interest expense															212,000	382,000	422,000	771,000
Amortization of debt issuance costs																171,000		347,000
Accured interest															1,600,000		1,600,000
Repayments of Debt																	5,700,000
Accredited Investors [Member] | Securities Purchase Agreement [Member]
Short-term Debt [Line Items]
Principal amount													$ 550,500
Debt instrument, interest rate													10.00%
Debt instrument, effective percentage													10.00%
Convertible Notes Payable, Current													$ 499,950
Debt Instrument, Convertible, Conversion Price | $ / shares												$ 0.50
Weighted average price of common stock												70.00%
Debt conversion rate												60.00%
Conversion price adjusted for stock splits, stock combinations and similar events (in dollars per share) | $ / shares												$ 0.05
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Short-term Debt [Line Items]
Warrant term													5 years
Debt discount to be amortized													$ 322,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]
Short-term Debt [Line Items]
Principal amount															550,500		550,500
Interest expense															25,000	35,000	50,000	55,000
Amortization of debt issuance costs																18,000		30,000	$ 38,000
Accured interest															$ 99,000		$ 99,000
Amortization of debt discount													21,000			$ 171,000		276,000
Debt default interest rate											18.00%
Debt conversion into shares value				$ 25,900
Debt conversion into shares | shares				518,000
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt Issuance Costs, Net													53,000
Amortization of debt discount													$ 30,000
Holders [Member] | Convertible Debt [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate															125.00%		125.00%
Holders [Member] | Convertible Debt [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																				125.00%
Holders [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate															140.00%		140.00%
Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Principal amount	$ 66,500				$ 52,778
Debt Issuance Costs, Net					$ 2,000										$ 1,000		$ 1,000
Debt instrument, interest rate	10.00%
Debt instrument, effective percentage	5.00%				10.00%
Interest expense															1,700		2,900	$ 0
Amortization of debt issuance costs															400		700
Accured interest															$ 2,000		$ 2,000
Convertible Notes Payable, Current					$ 47,500
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.075			$ 0.05	$ 0.07
Warrant term	7 months 6 days				1 year										2 months 12 days		2 months 12 days
Debt discount to be amortized															$ 3,000		$ 3,000
Amortization of debt discount															11,000		29,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.08				$ 0.08
Unamortized Debt Issuance Expense															5,700		5,700
Debt Instrument, Convertible, Conversion Ratio					0.70
Warrants issued | shares				301,592	753,968
Notes Payable															52,778		52,778
Debt Instrument, Unamortized Discount, Current															$ 100		$ 100
Secured Debt	$ 63,000
Warrants and Rights Outstanding	$ 76,000
Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs	0.48
Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs															0.09		0.09
Investor and lender [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs	302.11														405		405
Investor and lender [Member] | Secured Promissory Note [Member]
Short-term Debt [Line Items]
Principal amount			$ 66,667
Debt Issuance Costs, Net															$ 21,000		$ 21,000
Debt instrument, effective percentage			10.00%
Accured interest															$ 1,500		$ 1,500
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.075		$ 0.075
Debt conversion rate		70.00%
Warrant term	11 months 15 days														1 year		1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.095		$ 0.095
Deemed dividend	$ 88,893
Debt Instrument, Unamortized Discount, Current															$ 66,667		$ 66,667
Secured Debt			$ 60,000
Investor and lender [Member] | Secured Promissory Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs															0.89		0.89
Investor and lender [Member] | Secured Promissory Note [Member] | Measurement Input, Price Volatility [Member]
Short-term Debt [Line Items]
Fair value of warrants measurement inputs															240.64		240.64
Investor and lender [Member] | Warrant [Member] | Senior Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Debt discount to be amortized	$ 61,000														$ 32,000		$ 32,000
Investor and lender [Member] | Warrant [Member] | Secured Promissory Note [Member]
Short-term Debt [Line Items]
Debt discount to be amortized			$ 34,000
Investor and lender [Member] | Convertible Debt [Member] | Senior Secured Convertible Promissory Note Two [Member]
Short-term Debt [Line Items]
Debt discount to be amortized					$ 2,000

Licensing Agreements (Details N

Licensing Agreements (Details Narrative) - USD ($)	Dec. 23, 2019	Mar. 16, 2018	May 31, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Entity Listings [Line Items]
Other income					$ 40,000		$ 40,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member]
Entity Listings [Line Items]
Common stock issued			51,988
Fair value of common stock issued			$ 75,000
Proceeds form sale of intangible asset	$ 45,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member] | Upon Execution of Agreement [Member]
Entity Listings [Line Items]
Payables on intellectual property					20,000		20,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member] | Achievement of Performance Obligation [Member]
Entity Listings [Line Items]
Payables on intellectual property					25,000		25,000
Les Laboratories Servier License Agreement [Member]
Entity Listings [Line Items]
Payments for royalties				$ 0	0	$ 0	0
Novosom Agreement [Member]
Entity Listings [Line Items]
Other income					$ 25,000		$ 25,000
License Of DiLA Assets [Member] | Accrued Liabilities [Member]
Entity Listings [Line Items]
Upfront payment agreement for license agreement		$ 200,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Dec. 31, 2020USD ($)
Related Party Transactions [Abstract]
Due to Related Parties	$ 4,000

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights (Details)	Jun. 30, 2021shares
Class of Stock [Line Items]
Warrant shares	59,836,767
Expiring in 2021	343,750
Expiring in 2023	33,504,180
Expiring in 2024	1,135,452
Expiring in 2025	22,908,932
Expiring in 2026	1,944,453
Convertible Notes [Member]
Class of Stock [Line Items]
Warrant shares	25,650,184
Expiring in 2024	800,000
Expiring in 2025	22,905,731
Expiring in 2026	1,944,453
Other [Member]
Class of Stock [Line Items]
Warrant shares	348,733
Expiring in 2023	10,080
Expiring in 2024	335,452
Expiring in 2025	3,201
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	343,750
Expiring in 2021	343,750
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	30,405,600
Expiring in 2023	30,405,600
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrant shares	3,088,500
Expiring in 2023	3,088,500

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)	Jun. 08, 2021USD ($)shares	Mar. 19, 2021USD ($)$ / sharesshares	Oct. 30, 2019USD ($)shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019shares	Jul. 31, 2018shares	Apr. 30, 2018shares	Aug. 31, 2015shares	Mar. 31, 2014shares
Class of Stock [Line Items]
Preferred Stock, Shares Authorized				100,000		100,000		100,000
Stated value per share | $ / shares				$ 0.01		$ 0.01		$ 0.01
Accrued dividends | $	$ 10,000
Number of shares in accrued dividends	101,010
Number of shares issued	53,571
Warrants outstanding				59,836,767		59,836,767
Dividends, preferred stock | $				$ 392,000	$ 382,000	$ 1,274,000	$ 765,000
2020 Term Loan [Member]
Class of Stock [Line Items]
Number of shares issued		518,000
Accrued interest | $		$ 25,900
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Warrants outstanding				3,088,500		3,088,500
Series E Warrants [Member]
Class of Stock [Line Items]
Common stock converted, value | $		$ 25,900
Number of shares converted		518,000
Warrants outstanding				30,405,600		30,405,600
Series E Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares		$ 0.50
Series E Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares		$ 0.05
Series E Preferred [Member]
Class of Stock [Line Items]
Number of shares converted	8
Warrant [Member]
Class of Stock [Line Items]
Common stock for a cashless exercise	75,000					75,000
Adjustable warrants, shares				58,344,284		58,344,284
Series F Warrants [Member]
Class of Stock [Line Items]
Value of converted shares | $		$ 25,900
Number of shares issued upon conversion		518,000
Series F Warrants [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares		$ 0.50
Series F Warrants [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant exercise price shares upon conversion of debt | $ / shares		$ 0.05
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated, shares				1,000		1,000
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock designated, shares				90,000		90,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized				1,200		1,200		1,200
Preferred stock designated, shares													1,200
Stated value per share | $ / shares				$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares outstanding				100		100		100
Preferred stock, shares issued				100		100		100
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized				220		220		220
Preferred stock designated, shares												220
Stated value per share | $ / shares								$ 0.01
Preferred stock, shares outstanding				40		40		40
Preferred stock, shares issued				40		40		40
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized								3,500
Preferred stock designated, shares											3,500
Stated value per share | $ / shares								$ 0.01
Preferred stock, shares outstanding				3,450		3,450		3,458
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized				2,200		2,200		2,200
Preferred stock designated, shares										2,200
Stated value per share | $ / shares				$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares outstanding				361		361		361
Number of shares repurchased			20
Warrants to purchase shares of common stock			150,000
Stock repurchase | $			$ 100,000
Value of warrants held | $			$ 100,000
Accrued dividends | $						$ 418,000		$ 347,000
Preferred stock, shares issued				361		361		361
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized				6,000		6,000		6,000
Preferred stock designated, shares									6,000
Stated value per share | $ / shares				$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares issued				0		0		0
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares				$ 5,000		$ 5,000
Preferred stock liquidation preference per share | $ / shares				5,100		$ 5,100
Preferred Stock, Voting Rights						voting rights of 666.67 votes per share
Common stock at a conversion price, per share | $ / shares				$ 7.50		$ 7.50
Preferred stock, shares outstanding				100		100		100
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares				$ 5,000		$ 5,000
Preferred stock liquidation preference per share | $ / shares				300		$ 300
Preferred Stock, Voting Rights						voting rights of 1,250 votes per share
Common stock at a conversion price, per share | $ / shares				$ 4		$ 4
Preferred stock, shares outstanding				40		40		40
Preferred stock stated dividend rate						5.00%
Warrants outstanding				343,750		343,750
Series E Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares				$ 5,000		$ 5,000
Common stock at a conversion price, per share | $ / shares				$ 0.50		$ 0.50
Preferred stock stated dividend rate						8.00%
Anti-dilution price protection, expiration date						Feb. 10, 2020
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Deemed dividend | $		$ 390,000
Warrants outstanding				30,405,600		30,405,600
Dividends, preferred stock | $						$ 4,400,000		$ 3,700,000
Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs		0.16
Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs		2.6227
Series E Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term		5 months 4 days
Series E Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term		4 months 28 days
Series F Convertible Preferred Stock and Warrants [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares				$ 5,000		$ 5,000
Common stock at a conversion price, per share | $ / shares				$ 0.50		$ 0.50
Preferred stock stated dividend rate						8.00%
Anti-dilution price protection, expiration date						Feb. 10, 2020
Warrants term description						five years
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Deemed dividend | $		$ 31,000
Warrants outstanding				3,088,500		3,088,500
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs		0.16
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Fair value of warrants measurement inputs		262.27
Series F Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant term		6 months 10 days
Series F Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant term		5 months 15 days
Series G Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stated value per share | $ / shares				$ 5,000		$ 5,000
Common stock at a conversion price, per share | $ / shares				$ 0.50		$ 0.50
Preferred stock stated dividend rate						8.00%
Preferred stock, shares issued				0		0

Share-based Payment Arrangement

Share-based Payment Arrangement, Option, Activity (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Payment Arrangement [Abstract]
Options Outstanding Beginning | shares	391,350
Options outstanding, weighted average exercise price, beginning | $ / shares	$ 0.58
Options granted | shares
Options granted, weighted average exercise price | $ / shares
Options expired / forfeited | shares	(3,800)
Options expired/forfeited, weighted average exercise price | $ / shares	$ 2.60
Options Outstanding Ending | shares	387,550
Options outstanding, weighted average exercise price, ending | $ / shares	$ 0.99
Options Exercisable | shares	387,550
Exercisable, weighted average exercise price | $ / shares	$ 0.99

Share-based Payment Arrangeme_2

Share-based Payment Arrangement, Option, Exercise Price Range (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Numbers outstanding | shares	387,550
Weighted- Average Remaining Contractual Life (Years)	1 year 9 months 21 days
Weighted average exercise price	$ 0.99
Number exercisable | shares	387,550
Weighted average exercise price	$ 0.99
Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, lower	0.98
Range of exercise prices, upper	$ 1
Numbers outstanding | shares	383,500
Weighted- Average Remaining Contractual Life (Years)	1 year 9 months 29 days
Weighted average exercise price	$ 0.98
Number exercisable | shares	383,500
Weighted average exercise price	$ 0.98
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper	$ 1.70
Numbers outstanding | shares	4,050
Weighted- Average Remaining Contractual Life (Years)	6 months 7 days
Weighted average exercise price	$ 1.70
Number exercisable | shares	4,050
Weighted average exercise price	$ 1.70

Stock Incentive Plans (Details

Stock Incentive Plans (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock- based compensation expense	$ 0	$ 10,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Series F Convertible Preferred Stock [Member]	Oct. 30, 2019USD ($)shares
Affiliate, Collateralized Security [Line Items]
Number of shares repurchased | shares	20
Warrants to purchase shares of common stock | shares	150,000
Stock repurchase | $	$ 100,000
Value of warrants held | $	$ 100,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Aug. 12, 2021USD ($)Integer$ / sharesshares	Jul. 31, 2021USD ($)shares	Jul. 29, 2021USD ($)shares	Jun. 28, 2021	Aug. 18, 2021USD ($)Integer$ / sharesshares	Aug. 07, 2021shares	Jul. 30, 2021	Jun. 30, 2021USD ($)shares	Dec. 31, 2020USD ($)
Subsequent Event [Line Items]
Gross sales percentage				500.00%
Warrant shares								59,836,767
Debt discount | $								$ 89,000	$ 79,000
Series D Preferred Stock [Member]
Subsequent Event [Line Items]
Warrant shares								343,750
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member]
Subsequent Event [Line Items]
Debt instrument effective percentage	10.00%				10.00%
Warrant shares	800,000				800,000
Principal amount | $	$ 220,500				$ 220,500
Proceeds from convertible debt | $	210,000				$ 210,000
Debt discount | $	$ 10,500
Shares issued for commitment fees, shares	100,000				100,000
Conversion price | $ / shares	$ 0.075				$ 0.075
Trading days | Integer	20				20
Warrant term	3 years				3 years
Warrant exercise price | $ / shares	$ 0.095				$ 0.095
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Minimum [Member]
Subsequent Event [Line Items]
Conversion price | $ / shares	$ 0.08				$ 0.08
Subsequent Event [Member] | Series D Preferred Stock [Member]
Subsequent Event [Line Items]
Warrant shares						343,750
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Conversion of stock, shares		500,000
Conversion of stock, amount | $		$ 250,000
Subsequent Event [Member] | January Convertible Note [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			550,000
Debt Conversion, Converted Instrument, Amount | $			$ 27,500
Subsequent Event [Member] | Secured Promissory Note [Member]
Subsequent Event [Line Items]
Debt instrument effective percentage							18.00%